Torsten Bürgermeister

Torsten Bürgermeister served as Chief Financial Officer of VERAXA Biotech AG, departing in July 2026 after four and a half years with the company. During his tenure, Bürgermeister oversaw the company's transition to becoming a publicly traded organization on the NASDAQ Capital Market under ticker 'VRXA' in June 2026. He worked closely with management and external stakeholders throughout all stages of the listing process.

Bürgermeister brings more than 20 years of professional and management experience in Finance and Business Development in global life science and technology companies. His background spans leadership positions at Molecular Health, BASF Pharma, Techem Energy Services, and Colt Telecom. He holds a Diploma in Business Administration from DHBW Mannheim.

At VERAXA, Bürgermeister was instrumental in managing the company's financial growth and capital structure during critical growth phases. In May 2026, he oversaw the securing of $27.5 million in senior secured note financing and a $50 million share purchase agreement to strengthen the company's financial position. Under his leadership, the company expanded its R&D facility in Heidelberg by more than 60% to support team growth and accelerate cancer therapy programs.

Career history

• Chief Financial Officer, VERAXA Biotech AG (2021-2026)
• Leadership positions at Molecular Health
• BASF Pharma
• Techem Energy Services
• Colt Telecom

What Torsten Bürgermeister could bring to future finance leadership roles: With over two decades of progressive finance and business development experience across life sciences and technology sectors, Bürgermeister brings deep expertise in capital management, public market navigation, and R&D investment strategy. His demonstrated ability to successfully guide a biotech company through NASDAQ IPO processes, secure major financing rounds, and manage multi-million-dollar facility expansions positions him well for senior CFO or finance leadership roles in scaled life sciences organizations requiring sophisticated capital allocation and corporate development capabilities.